Author

Patricia Aragon-Han

Observed names: P Aragon-Han, P.. Aragon-Han

Institution: Prometheus Biosciences (United States)

Observed institution: Prometheus Biosciences (United States)

OpenAlex ID: A5093787504

The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program

2025 · Stephen B. Hanauer, Esther A. Torres, et al. · Pharmaceutics · 2

CO48 A Non-Interventional Chart Review Study of Infliximab Precision-Guided Dosing Tool's Clinical Experience Program: Interim Analysis of Real-World Health Outcomes and Extrapolated Cost Savings

2024 · A. Shim, St.. Jacque S, et al. · Value in Health · 2

P966 The intra-patient variability of adalimumab clearance during an intensive sampling study of Crohn’s disease patients receiving maintenance therapy

2024 · A Strong, P Aragon-Han, et al. · Journal of Crohn s and Colitis

Works count: 3

Citation count: 4

H-index: 2

I10-index: